David G. Mutch
YOU?
Author Swipe
View article: Targeting RAD52 overcomes PARP inhibitor resistance in preclinical <i>Brca2</i>-deficient ovarian cancer model
Targeting RAD52 overcomes PARP inhibitor resistance in preclinical <i>Brca2</i>-deficient ovarian cancer model Open
BRCA -mutated ovarian cancer commonly develops resistance to poly (ADP-ribose) polymerase (PARP) inhibitors. Here, we investigated the DNA repair protein RAD52 as a potential target to overcome resistance. In analysis of The Cancer Genome …
View article: Supplemental Figure 1 from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response
Supplemental Figure 1 from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response Open
Supplemental Figure 1
View article: Supplementary Tables from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response
Supplementary Tables from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response Open
Supplemental Table S1, S2, S3.
View article: Data from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response
Data from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response Open
High-grade serous ovarian cancer (HGSC) accounts for more than 200,000 deaths each year. Despite recent advances in treating HGSC with neoadjuvant chemotherapy, the majority of patients ultimately develop chemotherapy resistance. HGSC is c…
View article: Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms
Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms Open
Tubo-ovarian high-grade serous carcinoma (HGSC) is a leading cause of gynecologic cancer mortality, largely due to the emergence of platinum resistance, which serves as the mainstay of chemotherapy. Here, we identify COPS5 as a therapeutic…
View article: NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025 Open
The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer and uterine sarcoma. The NCCN Cervical Uterine Panel meets at least annua…
View article: Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response
Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response Open
High-grade serous ovarian cancer (HGSC) accounts for more than 200,000 deaths each year. Despite recent advances in treating HGSC with neoadjuvant chemotherapy, the majority of patients ultimately develop chemotherapy resistance. HGSC is c…
View article: Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc’s Scholar Career Development Award and New Investigator Program
Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc’s Scholar Career Development Award and New Investigator Program Open
The GOG-F Scholar Career Development Award has demonstrated strong success in cultivating clinical trial leaders through structured mentorship and protected research time. The New Investigator Program has effectively fostered early-career …
View article: Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer
Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer Open
BACKGROUNDTreatment of tubo-ovarian high-grade serous carcinoma (HGSC) includes cytoreductive surgery, platinum-based chemotherapy, and often poly(ADP-ribose) polymerase (PARP) inhibitors. While homologous recombination (HR) deficiency is …
View article: Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer
Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer Open
Objective: Obesity is a major risk factor for endometrial cancer. In addition to hormone therapy with progestins, glucagon like peptide-1 receptor (GLP-1R) agonists such as semaglutide may be helpful to achieve weight loss during conservat…
View article: Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer
Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer Open
Background Ovarian cancer treatment includes cytoreductive surgery, platinum-based chemotherapy, and often poly (ADP-ribose) polymerase (PARP) inhibitors. Homologous recombination (HR)-deficiency is a well-established predictor of therapy …
View article: Supplementary Figure S3 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer
Supplementary Figure S3 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer Open
RAD51 expression and platinum chemotherapy response in vitro and in patient tumors
View article: Supplementary Table 5 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer
Supplementary Table 5 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer Open
Patient characteristics of FFPE validation cohort
View article: Supplementary Table 1 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer
Supplementary Table 1 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer Open
Summary of Antibodies
View article: Figure S3 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins
Figure S3 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins Open
Stromal cell expression of DDR2 is critical for migration of ovarian cancer cells, related to Figure 4
View article: Supplementary Table 4 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer
Supplementary Table 4 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer Open
Patient characteristics of FFPE discovery cohort
View article: Figure S3 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins
Figure S3 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins Open
Stromal cell expression of DDR2 is critical for migration of ovarian cancer cells, related to Figure 4
View article: Table S5 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins
Table S5 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins Open
Secretome
View article: Table S3 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins
Table S3 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins Open
Multivariate Analysis
View article: Supplementary Table 4 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer
Supplementary Table 4 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer Open
Patient characteristics of FFPE discovery cohort
View article: Table S4 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins
Table S4 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins Open
Metabolism pathways
View article: Supplementary Figure S2 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer
Supplementary Figure S2 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer Open
ɣH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids
View article: Supplementary Figure S1 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer
Supplementary Figure S1 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer Open
Flow diagram of HGSOC patient-derived samples used for RAD51 foci assay
View article: Figure S5 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins
Figure S5 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins Open
Stromal cell expression of DDR2 is critical for migration and invasion of ovarian cancer cells, related to Figure 7
View article: Supplementary Table 2 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer
Supplementary Table 2 from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer Open
Patient characteristics of patient-derived ovarian cancer cells
View article: Table S2 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins
Table S2 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins Open
Patient cohort
View article: Figure S2 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins
Figure S2 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins Open
Stromal cell expression of DDR2 is critical for clearance, related to Figure 3
View article: Data from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer
Data from RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer Open
Purpose: To determine the ability of RAD51 foci to predict platinum chemotherapy response in high-grade serous ovarian cancer (HGSOC) patient-derived samples. Experimental Design: RAD51 and γH2AX nuclear foci were evaluated by immunofluore…
View article: Figure S6 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins
Figure S6 from Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins Open
Tumor LOXL2 and DDR2 expression correlates with survival